Search Result
Results for "
antisecretory
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-108287
-
|
Others
|
Endocrinology
|
Trithiozine is an orally active antisecretory and antiulcer agent. Trithiozine can be used for the research of peptic ulcer disease and hypersecretory disorders .
|
-
-
- HY-B1806A
-
Pathilon chloride
|
mAChR
|
Neurological Disease
Inflammation/Immunology
|
Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus .
|
-
-
- HY-79135
-
SOM230 ditrifluoroacetate; Pasireotide TFA salt
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-W373206
-
|
Others
|
Metabolic Disease
|
Triampizine is an effective gastric antisecretory agent. Triampizine does not have the side effects commonly associated with anticholinergic agents. Triampizine may react with the excipient magnesium stearate. Triampizine can be used in the research of hyperacidity .
|
-
-
- HY-108768
-
SOM230 pamoate
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-16381B
-
SOM230 (diaspartate)
|
Somatostatin Receptor
|
Neurological Disease
Cancer
|
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-79136
-
SOM230 L-aspartate
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-B0305
-
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity .
|
-
-
- HY-16381
-
SOM230
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-16381A
-
SOM230 acetate
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
-
- HY-N10763
-
|
Others
|
Endocrinology
|
N-Methylcorydaldine, an alkaloid, shows promising anti-secretory activity .
|
-
-
- HY-15295
-
TAK-438
|
Proton Pump
|
Metabolic Disease
|
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
|
-
-
- HY-100007A
-
TAK-438 hydrochloride
|
Proton Pump
Bacterial
|
Infection
Endocrinology
|
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
|
-
-
- HY-100007
-
TAK-438 free base
|
Proton Pump
Bacterial
|
Endocrinology
|
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
|
-
-
- HY-15541
-
-
-
- HY-19048
-
-
-
- HY-N12840
-
|
Others
|
Metabolic Disease
|
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .
|
-
-
- HY-15538
-
-
-
- HY-100007R
-
|
|
Endocrinology
|
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
|
-
-
- HY-121406
-
-
-
- HY-18337
-
-
-
- HY-B0758
-
|
Others
|
Inflammation/Immunology
|
Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties .
|
-
-
- HY-129471
-
|
Endogenous Metabolite
|
Inflammation/Immunology
|
Arbaprostil is an orally active PGE1 (HY-B0131) analog. Arbaprostil protects the gastrointestinal mucosa from stomach acid and other irritants, promotes healing rate of gastric ucler through the antisecretory effect .
|
-
-
- HY-N7031
-
(±)-Peganine
|
Proton Pump
|
Inflammation/Immunology
|
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H +-K +-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .
|
-
-
- HY-118091A
-
LY300502
|
Others
|
Cancer
|
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .
|
-
-
- HY-W230975
-
(E/Z)-Bioperine; (E/Z)-1-Piperoylpiperidine
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
(E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease .
|
-
-
- HY-B0305A
-
HOE 760
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .
|
-
-
- HY-100413
-
|
Proton Pump
|
Inflammation/Immunology
|
CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
|
-
-
- HY-17507
-
BY1023; SKF96022
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-17507A
-
BY1023 sodium; SKF96022 sodium
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-17507B
-
BY1023 sodium hydrate; SKF96022 sodium hydrate
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-B1789A
-
|
mAChR
|
Neurological Disease
|
Telenzepine dihydrochloride is a selective and orally active muscarinic M1 receptor antagonist with a Ki of 0.94 nM. Telenzepine dihydrochloride inhibits gastric acid secretion and has antiulcer effects .
|
-
-
- HY-17507S
-
BY1023-d6; SKF96022-d6
|
Isotope-Labeled Compounds
Proton Pump
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
-
- HY-17507S1
-
BY1023-d3; SKF96022-d3
|
Isotope-Labeled Compounds
Proton Pump
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
-
- HY-17507AR
-
BY1023 sodium (Standard); SKF96022 sodium (Standard)
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-19778
-
-
-
- HY-B0160
-
FRG-8813
|
Histamine Receptor
|
Metabolic Disease
Endocrinology
|
Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-16381A
-
SOM230 acetate
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
-
- HY-106128
-
BN 52080
|
Peptides
|
Infection
|
Lagatide (BN 52080), a heptapeptide, is a short C-terminal analog of sorbin. Lagatide has proabsorptive and antisecretory effect in the different parts of the intestine. Lagatide can be used for the research of chronic diarrhea .
|
-
- HY-16381
-
SOM230
|
Somatostatin Receptor
|
Endocrinology
Cancer
|
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17507S
-
|
Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
-
- HY-17507S1
-
|
Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: